Olaris CEO Elected to Personalized Medicine Coalition Board of Directors
Dr. Elizabeth O’Day will lead personalized medicine investment and adoption efforts globally during three-year term
June 9, 2020 — Olaris, a precision medicine company that is working to fundamentally change how diseases are treated, today announced that The Personalized Medicine Coalition (PMC) has elected Olaris CEO and Founder Dr. Elizabeth O’Day to serve a three-year term on the PMC Board of Directors.
Founded in 2004, The Personalized Medicine Coalition represents innovators, scientists, patients, providers and payers, to promote the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and the health system. Believing that paradigm shifts, especially in medicine, do not happen just because the science and new technologies suggest they should, the Coalition supports investment in and adoption of personalized medicine through education, advocacy, and evidence development.
“Over the last decade, the growth of the personalized medicine industry has demonstrated that tailoring treatment and prevention plans to each individual patient can dramatically improve health outcomes,” said Dr. Elizabeth O’Day. “I’ve dedicated my life to the advancement of personalized medicine, and during my term on the PMC Board of Directors, I look forward to collaborating with stakeholders across academia, industry, and government to work towards a future where access to personalized medicine is ubiquitous.”
Dr. O’Day brings an extensive personalized medicine background in both academia and industry to PMC’s board of directors. She is the CEO and Founder of Olaris, Inc., a precision medicine company that has developed a metabolomics platform and machine learning algorithms to determine which patients will benefit from a specific drug. Dr. O'Day is also the co-chair of the World Economic Forum’s Global Future Council on Biotechnology, and a member of Scientific American's Steering Committee for the publication’s annual "Top 10 Emerging Technologies." She received her PhD from Harvard University, where she was a National Science Fellow, an MPhil in Chemistry from the University of Cambridge where she was a Churchill Fellow and a BS in Biochemistry from Boston College where she was a Finnegan Award winner, Beckman Scholar, Goldwater Scholar and graduated summa cum laude.
In the announcement of Dr. O’Day and Tempus SVP of External Affairs Lauren Silvus, PMC Board Chair Jay G. Wohlgemuth, M.D., Chief Medical Officer, Senior Vice President, Quest Diagnostics, said, “Both of these new board members are collaborative leaders who are committed to working across sectors to advance personalized medicine for the benefit of patients and health systems. I am confident that both Liz and Lauren will help the Coalition in its efforts to promote the understanding and adoption of personalized medicine across all sectors.”
To learn more about the Personalized Medicine Coalition, visit www.personalizedmedicinecoalition.org.
Olaris is working to fundamentally change how diseases are treated. The company’s metabolomics platform and machine learning algorithms produce Biomarkers of Response (BoR), which removes the guesswork when treating an individual patient’s disease. To learn more, visit www.olarisbor.com.